最近发现和开发的AXL抑制剂作为抗瘤剂
Zihang Liu1, Li Chen2, Jifa Zhang3
1Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Center, State Key Laboratory of Respiratory Health and Multimorbidity, Laboratory of Neuro-system and Multimorbidity, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, Sichuan, China.
准AXL,一个受体氨酸激酶,显示了癌症治疗的希望. 新型AXL抑制剂和降解剂为克服耐药性和提高各种癌症治疗疗效提供了新的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- AXL受体氨酸激酶 (RTK) 参与了关键的细胞过程,包括上皮细胞-介质细胞过渡 (EMT),血管生成,细胞亡,免疫调节和化疗耐药性.
- AXL信号的失调与各种癌症的进展和耐治疗性有关.
研究的目的:
- 为AXL的结构和生物功能提供全面的概述.
- 分析AXL与各种癌症类型之间的相关性.
- 批判性地评估小分子AXL抑制剂的结构-活性关系.
主要方法:
- 文献综述和对AXL现有研究的分析.
- 对AXL抑制剂的临床试验数据的检查.
- 在细胞模型中分析AXL抑制剂的结构-活性关系 (SAR).
主要成果:
- 包括BGB324在内的AXL抑制剂在黑色素瘤和非小细胞肺癌中表现出有效性.
- AXL降解剂代表了一种新的治疗策略,以克服传统抑制剂的局限性.
- 了解SAR对于开发强效和选择性的AXL抑制剂至关重要.
结论:
- 向AXL是癌症治疗的可行治疗策略.
- AXL降解剂为克服抵抗机制提供了一个有希望的途径.
- 未来的研究应该专注于开发基于SAR和多样化的开发策略的创新型AXL抑制剂.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
相关概念视频
Drug Discovery: Overview
Drugs that Destabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Drugs that Stabilize Microtubules
